Lv6
2780 积分 2022-01-11 加入
Discovery of lirafugratinib (RLY-4008), a highly selective irreversible small-molecule inhibitor of FGFR2
2天前
已完结
Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension
1个月前
已完结
Phenotype-Led Identification of IL-10 Upregulators in Human CD4+ T-cells and Elucidation of Their Pharmacology as Highly Selective CDK8/CDK19 Inhibitors
1个月前
已完结
Conversion of antigen-specific effector/memory T cells into Foxp3-expressing T reg cells by inhibition of CDK8/19
2个月前
已完结
Therapeutic Small Interfering RNA Targeting Complement C3 in a Mouse Model of C3 Glomerulopathy
2个月前
已完结
A Bispecific γδ T-cell Engager Targeting EGFR Activates a Potent Vγ9Vδ2 T cell–Mediated Immune Response against EGFR-Expressing Tumors
2个月前
已完结
Metabolic coordination of T cell quiescence and activation
2个月前
已完结
IgA nephropathy
3个月前
已完结
Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy
3个月前
已完结
Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial
5个月前
已完结
皖公网安备34019202002308
